2017 annual financial data
Inhibikase Therapeutics 2017 Net income growth
Direct answer
Net income growth was 30.64%.
Operating income was -405,130 USD and net income was -436,075 USD.
Operating cash flow was -126,391 USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 2,060,937 USD
- Operating income
- -405,130 USD
- Net income
- -436,075 USD
- Operating cash flow
- -126,391 USD